EBS Emergent Biosolutions Inc
4,654
$5.27
$0.44
(7.71%)
| Watchers | 4,654 |
| 52-Wk Low | $1.42 |
| 52-Wk High | $9.96 |
| Market Cap | $276.16M |
| Volume | 1.76M |
| 52-Wk High | $9.96 |
| 52-Wk Low | $1.42 |
Looking Into Emergent BioSolutions's Recent Short InterestBenzinga • 8 days ago
read more...
Share to Feed
Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171.08%.
read more...
Futures Rise As Dovish Fed Boosts Sentiment, Reverse Bizarre Post-Powell Slide
After a bizarre reversal when US stocks first slumped and then dumped after Powell's very dovish FOMC...
Investors eyeing a purchase of Emergent BioSolutions Inc (EBS) shares, but tentative about paying the going market price of 2.33/share, might benefit from considering selling puts among the...
Appoints Abigail Abbey Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE...
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN Nasal Spray and build on its longstanding...
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed No Action Indicated or NAI...
Emergent Biosolutions Non-GAAP EPS of -$0.77 misses by $0.45, revenue of $276.6M beats by $2.6M...
Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth...
This is a signal that EBS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...